Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis
- PMID: 24440215
- PMCID: PMC4101072
- DOI: 10.1016/j.cgh.2013.12.036
Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis
Abstract
Background & aims: Coffee consumption has been associated with decreased risk of liver disease and related outcomes. However, coffee drinking has not been investigated among patients with cholestatic autoimmune liver diseases, primary biliary cirrhosis (PBC), or primary sclerosing cholangitis (PSC). We investigated the relationship between coffee consumption and risk of PBC and PSC in a large North American cohort.
Methods: Lifetime coffee drinking habits were determined from responses to questionnaires from 606 patients with PBC, 480 with PSC, and 564 healthy volunteers (controls). Patients (those with PBC or PSC) were compared with controls by using the Wilcoxon rank sum test for continuous variables and c(2) method for discrete variables. Logistic regression was used to analyze the estimate of the effects of different coffee parameters (time, frequency, and type of coffee consumption) after adjusting for age, sex, smoking status, and education level.
Results: Patients with PBC and controls did not differ in coffee parameters. However, 24% of patients with PSC had never drunk coffee compared with 16% of controls (P < .05), and only 67% were current drinkers compared with 77% of controls (P < .05). Patients with PSC also consumed fewer lifetime cups per month (45 vs 47 for controls, P < .05) and spent a smaller percentage of their lifetime drinking coffee (46.6% vs 66.7% for controls, P < .05). These differences remained significant in a multivariate model. Among PSC patients with concurrent ulcerative colitis, coffee protected against proctocolectomy (hazard ratio, 0.34; P < .001).
Conclusions: Coffee consumption is lower among patients with PSC, but not PBC, compared with controls.
Keywords: Biliary Inflammation; Caffeine; Cholestasis; Risk Factor; UC.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Comment in
-
Coffee: a panacea or snake oil for the liver?Clin Gastroenterol Hepatol. 2014 Sep;12(9):1569-71. doi: 10.1016/j.cgh.2014.04.015. Epub 2014 Apr 24. Clin Gastroenterol Hepatol. 2014. PMID: 24768813 Free PMC article. No abstract available.
References
-
- Andersen LF, Jacobs DR, Jr, Carlsen MH, Blomhoff R. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women’s Health Study. Am J Clin Nutr. 2006;83(5):1039–46. Epub 2006/05/11. - PubMed
-
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens. 2005;23(5):921–8. Epub 2005/04/19. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
